BiotechTube

Rosuvastatin 40mg + Placebo

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease, Atherosclerotic Plaque, Coronary Computed Tomography Angiography, Statin Therapy, Multidetector Computed Tomography, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Vascular Diseases, Hyperlipidemia

Trial Timeline

May 28, 2025 → Dec 15, 2028

NCT ID
NCT06603363

About Rosuvastatin 40mg + Placebo

Rosuvastatin 40mg + Placebo is a pre-clinical stage product being developed by HeartFlow for Coronary Artery Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06603363. Target conditions include Coronary Artery Disease, Atherosclerotic Plaque, Coronary Computed Tomography Angiography.

Hype Score Breakdown

Clinical
5
Activity
2
Company
5
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT06603363Pre-clinicalRecruiting

Competing Products

20 competing products in Coronary Artery Disease

See all competitors
ProductCompanyStageHype Score
EvolocumabHeartFlowApproved
80
High intensity lipid loweringHeartFlowPre-clinical
18
ExenatideEli LillyPhase 3
77
Clopidogrel treatment groupYuhanApproved
85
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
85
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
77
statins, ezetimibe + Combination therapyYuhanApproved
85
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
85
clopidogrel + prasugrelDaiichi SankyoPhase 1
33
PrasugrelDaiichi SankyoApproved
85
ADP receptor inhibitorsDaiichi SankyoPre-clinical
23
Pactimibe, CS-505Daiichi SankyoPhase 2
52
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
52
prasugrel + clopidogrelDaiichi SankyoPhase 1
33
Prasugrel + ClopidogrelDaiichi SankyoApproved
85
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
77
Placebo + PrasugrelDaiichi SankyoPhase 3
77
30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
85

Other Products from HeartFlow

EvolocumabApproved
80
High intensity lipid loweringPre-clinical
18